3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
2
Vascular Diseases
1
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Interventions
Dexamethasone
12
Bortezomib
9
Lenalidomide
6
Cyclophosphamide
5
isatuximab
3
fludarabine
3
daratumumab
3
Granulocyte Colony-Stimulating Factor
3
pomalidomide
2
filanesib
2
dacetuzumab
2
Tacrolimus
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
Clinical Protocols
2
Calcium Dobesilate
2
Alemtuzumab
2
plerixafor
1
nirogacestat
1
fludarabine phosphate
1
ficlatuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tissue Banks
1
Thalidomide
1
Stem Cell Transplantation
1
Ranitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraproteinemias
×
Erlotinib Hydrochloride
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled